Adalimumab biosimilar (Zydus Cadila)

阿达木单抗生物类似药 (Zydus Cadila)

Report date: 2022/05/16 08:59:05

Base Information

Drug NameAdalimumab biosimilar (Zydus Cadila)
Drug Alias Name阿达木单抗生物仿制药 (Zydus Cadila)Recombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (Zydus Cadila)adalimumab biosimilar重组抗肿瘤坏死因子-α全人源单抗 (Zydus Cadila)重组抗TNFa全人单抗 (Zydus Cadila) +[8] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, RheumatoidArthritis, JuvenileSpondylitis, Ankylosing +[4] 
Global Approved IndicationsArthritis, RheumatoidArthritis, JuvenileSpondylitis, Ankylosing +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2014/12/09
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesZydus Cadila
China Registration ClassN/A

Develop Information

Active CompaniesZydus Cadila
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidArthritis, JuvenileSpondylitis, Ankylosing +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A